SMS Intervention for Attention Deficit Hyperactivity Disorder (ADHD)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Attention Deficit Hyperactivity Disorder (ADHD)+2 More
SMS Intervention - Other
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This study will assess the efficacy of the text messaging (SMS-based) disease management intervention to improve adherence to stimulants in adults with Attention Deficit/Hyperactivity Disorder (ADHD). Participants in the study will receive customized text messages twice a day, every day, for a duration of 9 months. The text messages will include reminders to adhere to the individualized medication regimen, reminders to call their clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about ADHD and its treatment.

Eligible Conditions
  • Attention Deficit Hyperactivity Disorder (ADHD)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Attention Deficit Hyperactivity Disorder (ADHD)

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 9 months

9 months
Adherence to Stimulants

Trial Safety

Safety Progress

1 of 3

Other trials for Attention Deficit Hyperactivity Disorder (ADHD)

Trial Design

1 Treatment Group

SMS Intervention
1 of 1
Experimental Treatment

125 Total Participants · 1 Treatment Group

Primary Treatment: SMS Intervention · No Placebo Group · N/A

SMS Intervention
Other
Experimental Group · 1 Intervention: SMS Intervention · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 9 months

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,673 Previous Clinical Trials
30,828,531 Total Patients Enrolled
58 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
7,908 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)
ShireIndustry Sponsor
455 Previous Clinical Trials
92,722 Total Patients Enrolled
71 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
11,108 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)
Joseph Biederman, MDPrincipal InvestigatorMassachusetts General Hospital
24 Previous Clinical Trials
6,309 Total Patients Enrolled
13 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
4,379 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)

Eligibility Criteria

Age 18 - 65 · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 27th, 2021

Last Reviewed: October 14th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
Alabama33.3%
Illinois33.3%
Michigan33.3%
How old are they?
18 - 65100.0%
What site did they apply to?
Massachusetts General Hospital100.0%
What portion of applicants met pre-screening criteria?
Met criteria60.0%
Did not meet criteria40.0%